All News
China’s CanSino in mRNA vaccine deal with AstraZeneca
CanSino Biologics (6185.HK) has agreed with AstraZeneca (AZN.L) to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.
Hong Kong removes requirement to flag China risk in listing applications
Hong Kong stock exchange has removed a China-risk section for mainland-incorporated companies in its listing application rules with effect from Tuesday, which the bourse said was to align disclosure requirements for IPO-aspirants from other countries and the scrutiny level remains the same.
Biden order proposes new restrictions on China tech investment
President Biden signed an executive order Wednesday aimed at curbing the flow of U.S. investment and management know-how into a limited range of Chinese firms that the administration fears could fuel Beijing’s military ambitions.
China’s medical exports tumble as world moves on from COVID
China's medical exports fell 26.1% year-on-year in the first half of 2023, dragged down by weaker demand amid a sluggish global economic recovery and a high base for comparison.
Sunbird Bio Merges with Glympse Bio to Accelerate Development of Proprietary Protein-Based Diagnostic Technologies
Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced that they have completed a merger with Glympse Bio to accelerate development of the companies’ protein-based diagnostic platforms.
Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug
Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE).
Dr. Reddy’s Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).
SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.
Lemonex announces approval of IND application for mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial
Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL® on 21st of July.
Astellas to Open New Life Sciences Facility in DivcoWest’s Cambridge Crossing Neighborhood
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and DivcoWest, a DivCore Capital Company, announced today plans for Astellas to open a new state-of-the-art life sciences facility at 441 Morgan Avenue, in the Cambridge Crossing (CX) neighborhood in Cambridge, Mass.
